$SLS is a Ticking Time Bomb: 261% CTB, 12 Days to Cover, and Phase 3 Data Imminent. Shorts are Trapped in a Burning Room.
$SLS
AI SUMMARY — SLS has extremely high short interest metrics (261% cost-to-borrow, 12 days to cover) with Phase 3 clinical trial data expected imminently, creating potential for a major short squeeze. Key risks include the possibility of negative Phase 3 data which could trigger massive short covering losses, and volatility from biotech data announcements.
| TICKER | SLS |
USER | u/Dry-Communication912 |
| RATING |
BULLISH |
ENTRY |
$12.40
|
| POSITION |
N/A
|
BOOK VAL |
N/A |
| CURRENT |
$11.55 |
P&L % |
-6.83%
|
| CURR VAL |
N/A |
P&L $ |
N/A
|